内镜超声引导剪切波弹性成像用于肥胖及代谢功能障碍相关脂肪性肝病患者肝纤维化筛查:一项先导研究(含视频)
这项多中心横断面先导研究纳入62例接受EUS-SWE及肝活检的肥胖MASLD患者,评估EUS-SWE对肝纤维化分期的诊断准确性。EUS-SWE在判别显著纤维化(F2)和进展期纤维化(F3)方面优于FIB-4,在预测进展期纤维化和肝硬化方面优于VCTE;研究并计算了90%敏感度和90%特异度 cutoff 值。
要点
- 肥胖MASLD患者中,EUS-SWE判别F2和F3纤维化优于FIB-4。
- EUS-SWE预测进展期纤维化和肝硬化优于VCTE。
- EUS-SWE的90%敏感度cutoff:F2为7.50,F3为8.48,F4为11.30。
核心结论
- 在这项先导研究中,EUS-SWE在肥胖MASLD患者肝纤维化分期方面优于FIB-4和VCTE。
研究设计与样本
- 多中心、横断面研究,采用前瞻性收集的数据。
- 连续纳入接受EUS-SWE并随后进行肝活检的患者,共62例。
- 平均体重指数为40.74 kg/m2。
主要发现
- EUS-SWE判别显著纤维化(F2)优于FIB-4:AUROC 0.87 vs 0.61,P < .0048。
- EUS-SWE判别进展期纤维化(F3)优于FIB-4:AUROC 0.93 vs 0.63,P < .0001。
- EUS-SWE判别肝硬化(F4)与FIB-4相比:AUROC 0.95 vs 0.81,P = .099。
- EUS-SWE预测进展期纤维化和肝硬化优于VCTE:P = .0067和P = .0022。
- EUS-SWE的90%敏感度cutoff:F2为7.50,F3为8.48,F4为11.30;90%特异度cutoff:F2为9.82,F3为10.20,F4为14.60。
关键数值与推荐
- EUS-SWE的90%敏感度cutoff:F2为7.50,F3为8.48,F4为11.30。
- EUS-SWE的90%特异度cutoff:F2为9.82,F3为10.20,F4为14.60。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Liver fibrosis staging is challenging in patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). Liver biopsies are invasive, whereas noninvasive tests such as vibration-controlled transient elastography (VCTE) can be inaccurate in patients with obesity. We hypothesized that EUS-guided shear wave elastography (EUS-SWE) is more accurate for liver fibrosis staging in patients with MASLD and obesity; the aim of this pilot study was to test this hypothesis and establish optimal fibrosis stage cutoffs for EUS-SWE. METHODS: This was a multicenter, cross-sectional study from prospectively collected data. Consecutive patients who underwent EUS-SWE with subsequent liver biopsy were included. EUS-SWE was compared with Fibrosis-4 Index (FIB-4) and VCTE. Area under the receiver-operating characteristic (AUROC) curve analysis was performed, and 90% sensitivity and specific cutoffs were calculated to determine optimal cutoffs. RESULTS: Sixty-two patients were included. Mean body mass index was 40.74 kg/m2. EUS-SWE was superior to FIB-4 in discriminating significant fibrosis (F2; AUROC, .87 vs .61; P < .0048) and advanced fibrosis (F3; AUROC, .93 vs .63; P < .0001), but not cirrhosis (F4; AUROC, .95 vs .81; P = .099). EUS-SWE was superior to VCTE in predicting advanced fibrosis and cirrhosis (P = .0067 and P = .0022, respectively). The 90% sensitivity cutoffs for EUS-SWE were 7.50, 8.48, and 11.30 for F2, F3, and F4, and the 90% specificity cutoffs were 9.82, 10.20, and 14.60. CONCLUSIONS: In this pilot study, EUS-SWE was superior to FIB-4 and VCTE for liver fibrosis staging in patients with MASLD and obesity. (Clinical trial registration number: NCT05728697.).
引用
- Wang TJ, Jirapinyo P, Shah R, et al. EUS-guided shear wave elastography for fibrosis screening in patients with obesity and metabolic dysfunction-associated steatotic liver disease: a pilot study (with video). Gastrointest Endosc. 2024. PMID: 39481576. doi:10.1016/j.gie.2024.10.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。